Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study. Rathmann, J., Segelmark, M., Englund, M., & Mohammad, A. J. RMD Open, 9(1):e002949, March, 2023. Number: 1 Publisher: BMJ Specialist Journals Section: Epidemiology
Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study [link]Paper  doi  abstract   bibtex   
Objective To update the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) in a defined geographical area of southern Sweden. Methods The study area comprised 14 municipalities with a combined adult population (≥18 years) of 623 872 in 2019. All cases diagnosed with AAV in 1997–2019 in the study area were included in the estimate of incidence. Diagnosis of AAV was verified by case record review, and cases were classified using the European Medicines Agency algorithm. Point prevalence was estimated on 01 January 2020. Results Three hundred and seventy-four patients (median age 67.5 years, 47% female) were diagnosed with new-onset AAV during the study period. One hundred and ninety-two were classified as granulomatosis with polyangiitis (GPA), 159 as microscopic polyangiitis (MPA) and 23 as EGPA. The average annual incidence/million adults was 30.1 (95% CI 27.0 to 33.1) for AAV: 15.4 (95% CI 13.3 to 17.6) for GPA, 12.8 (95% CI 10.8 to 14.8) for MPA and 1.8 (95% CI 1.1 to 2.6) for eosinophilic GPA (EGPA). Incidence was stable during the study period, 30.3/million 1997–2003, 30.4/million 2004–2011 and 29.5/million 2012–2019. The incidence increased with age and was highest in age group 70–84 years (96/million adults). On 1 January 2020, the prevalence was 428/million adults and was higher in males than in females (480 vs 378/million). Conclusions The incidence of AAV in southern Sweden was found stable over the course of 23 years; while the prevalence has increased, which might indicate better management and treatment of AAV resulting in improved survival.
@article{rathmann_stable_2023,
	title = {Stable incidence but increase in prevalence of {ANCA}-associated vasculitis in southern {Sweden}: a 23-year study},
	volume = {9},
	copyright = {© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.},
	issn = {2056-5933},
	shorttitle = {Stable incidence but increase in prevalence of {ANCA}-associated vasculitis in southern {Sweden}},
	url = {https://rmdopen.bmj.com/content/9/1/e002949},
	doi = {10.1136/rmdopen-2022-002949},
	abstract = {Objective To update the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) in a defined geographical area of southern Sweden.
Methods The study area comprised 14 municipalities with a combined adult population (≥18 years) of 623 872 in 2019. All cases diagnosed with AAV in 1997–2019 in the study area were included in the estimate of incidence. Diagnosis of AAV was verified by case record review, and cases were classified using the European Medicines Agency algorithm. Point prevalence was estimated on 01 January 2020.
Results Three hundred and seventy-four patients (median age 67.5 years, 47\% female) were diagnosed with new-onset AAV during the study period. One hundred and ninety-two were classified as granulomatosis with polyangiitis (GPA), 159 as microscopic polyangiitis (MPA) and 23 as EGPA. The average annual incidence/million adults was 30.1 (95\% CI 27.0 to 33.1) for AAV: 15.4 (95\% CI 13.3 to 17.6) for GPA, 12.8 (95\% CI 10.8 to 14.8) for MPA and 1.8 (95\% CI 1.1 to 2.6) for eosinophilic GPA (EGPA). Incidence was stable during the study period, 30.3/million 1997–2003, 30.4/million 2004–2011 and 29.5/million 2012–2019. The incidence increased with age and was highest in age group 70–84 years (96/million adults). On 1 January 2020, the prevalence was 428/million adults and was higher in males than in females (480 vs 378/million).
Conclusions The incidence of AAV in southern Sweden was found stable over the course of 23 years; while the prevalence has increased, which might indicate better management and treatment of AAV resulting in improved survival.},
	language = {en},
	number = {1},
	urldate = {2023-04-06},
	journal = {RMD Open},
	author = {Rathmann, Jens and Segelmark, Mårten and Englund, Martin and Mohammad, Aladdin J.},
	month = mar,
	year = {2023},
	pmid = {36894194},
	note = {Number: 1
Publisher: BMJ Specialist Journals
Section: Epidemiology},
	keywords = {Epidemiology, Granulomatosis with polyangiitis, Systemic vasculitis},
	pages = {e002949},
}

Downloads: 0